Introduction Ulcerative colitis (UC) is a type of inflammatory bowel disease (IBD) affecting
the large intestine and carrying a heavy burden of morbidity for patients. Conventional …

Introduction: Biological agents are effective in ulcerative colitis (UC). Currently, 3 anti-TNF
agents (infliximab, adalimumab, and golimumab) and 1 anti-integrin agent (vedolizumab) …

Biologics have been emerging as promising therapies in ulcerative colitis (UC) patients who
are refractory to conventional medical treatment. This literature review aims to appraise the …

Biological agents have proven clinical efficacy in the treatment of ulcerative colitis (UC).
Their adverse effects have also been studied in a substantial number of primary studies and …

Objectives We compared the safety profile of biologic drugs in patients with moderately to
severely active ulcerative colitis (UC). Methods A systematic literature search was performed …

Background: In the last decade, the introduction of the first anti-tumor necrosis factor (TNF)-α
agent infliximab has revolutionized the treatment of ulcerative colitis (UC). However, this …

Backgrounds and aims There are currently no studies comparing histologic remission of
FDA-approved biologics for moderate to severe ulcerative colitis (UC), except for one head …

Background Biological therapies are increasingly used to treat ulcerative colitis (UC). Aim To
compare the efficacy of biologics in adults with moderately-to-severely active UC, stratified …

Background We conducted a systematic review and meta-analysis to evaluate the efficacy
and adverse event (AE)-associated tolerability of treatment with immunomodulators and …

To gain a better understanding of the effects of biologics, we evaluated clinical outcomes in
patients with moderate to severe exacerbations of ulcerative colitis (UC). This retrospective …